The Quick Reference Guide for Clinicians contains strategies and recommendations from the Public Health Service-sponsored Clinical Practice Guideline Treating Tobacco Use and Dependence: 2008 Update. The guideline was designed to assist clinicians; smoking cessation specialists; and healthcare administrators, insurers, and purchasers in identifying and assessing tobacco users and in delivering effective tobacco dependence interventions. It was based on an exhaustive systematic review and analysis of the extant scientific literature from 1975–2007 and uses the results of more than 50 meta-analyses. The Quick Reference Guide for Clinicians summarizes the guideline strategies for providing appropriate treatments for every patient. Effective treatments for tobacco dependence now exist, and every patient should receive at least minimal treatment every time he or she visits a clinician. The first step in the process—identification and assessment of tobacco use status—separates patients into three treatment categories: (1) tobacco users who are willing to quit should receive intervention to help in their quit attempt; (2) those who are unwilling to quit now should receive interventions to increase their motivation to quit; and (3) those who recently quit using tobacco should be provided relapse prevention treatment. Tobacco is the single greatest cause of disease and premature death in America today, and is responsible for more than 435,000 deaths annually. About 20 percent of adult Americans currently smoke, and 4,000 children and adolescents smoke their first cigarette each day. The societal costs of tobacco related death and disease approach $96 billion annually in medical expenses and $97 billion in lost productivity. However, more than 70 percent of all current smokers have expressed a desire to stop smoking; if they successfully quit, the result will be both immediate and long-term health improvements. Clinicians have a vital role to play in helping smokers quit. The analyses contained within the Clinical Practice Guideline Treating Tobacco Use and Dependence: 2008 Update demonstrated that efficacious treatments for tobacco users exist and should become a part of standard care giving. Research also shows that delivering such treatments is cost-effective. In summary, the treatment of tobacco use and dependence presents the best and most cost-effective opportunity for clinicians to improve the lives of millions of Americans nationwide.

This volume in the series Advances in Psychotherapy – Evidence-Based Practice provides health care providers with practical and evidence-based guidance on the diagnosis and treatment of nicotine and tobacco dependence. Tobacco use is the leading preventable cause of death in the world, and it is the only legally available consumer product that kills people when used entirely as intended. Research over the past several decades has led to the development of a number of evidence-based treatments for nicotine and tobacco dependence that can be delivered by health care professionals in a variety of primary and specialty care settings. This book aims to increase medical, mental health, and dental practitioners' access to empirically supported interventions for nicotine and tobacco dependence, with the hope that these methods will be incorporated into routine clinical practice. The book is both a compact "how-to" reference for clinicians and an ideal educational resource for students and for practice-oriented continuing education. The volume includes tables, boxed clinical pearls, and clinical vignettes, and the appendix includes clinical tools, patient handouts, and links to the top recommended websites for the download of additional patient materials.

"This guideline is an updated version of the 1996 Smoking Cessation Clinical Practice Guideline No. 18."--P. ii.

"Treating Tobacco Use and Dependence: 2008 Update"," is a product of the Tobacco Use and Dependence Guideline Panel, consortium representatives, consultants, and staff. This Guideline is an updated version that contains strategies and recommendations designed to assist clinicians; tobacco dependence treatment specialists; and health care administrators, insurers, and purchasers in delivering and supporting effective treatments for tobacco use and dependence. The recommendations were made as a result of a systematic review and meta-analysis of 11 specific topics identified by the Panel. The key recommendations of the updated Guideline are as follows: The overarching goal of these recommendations is that clinicians strongly recommend the use of effective tobacco dependence counseling and medication treatments to their patients who use tobacco, and that health systems, insurers, and purchasers assist clinicians in making such effective treatments available. 1. Tobacco dependence is a chronic disease that often requires repeated intervention and multiple attempts to quit. Effective treatments exist, however, that can significantly increase rates of long-term abstinence. 2. It is essential that clinicians and health care delivery systems consistently identify and document tobacco use status and treat every tobacco user seen in a health care setting. 3. Tobacco dependence treatments are effective across a broad range of populations. Clinicians should encourage every patient willing to make a quit attempt to use the counseling treatments and medications recommended in this Guideline. 4. Brief tobacco dependence treatment is effective. Clinicians should offer every patient who uses tobacco at least the brief treatments shown to be effective in this Guideline. 5. Individual, group, and telephone counseling are effective, and their effectiveness increases with treatment intensity. Two components of counseling are especially effective, and clinicians should use these when counseling patients making a quit attempt: Practical counseling (problemsolving/skills training); Social support delivered as part of treatment 6. Numerous effective medications are available for tobacco dependence, and clinicians should encourage their use by all patients attempting to quit smoking-except when medically contraindicated or with specific populations for which there is insufficient evidence of effectiveness (i.e., pregnant women, smokeless tobacco users, light smokers, and adolescents). Seven first-line medications (5 nicotine and 2 non-nicotine) reliably increase long-term smoking abstinence rates: Bupropion SR, Nicotine gum, Nicotine inhaler, Nicotine lozenge, Nicotine nasal spray, Nicotine patch, Varenicline; Clinicians also should consider the use of certain combinations of medications identified as effective in this Guideline. 7. Counseling and medication are effective when used by themselves for treating tobacco dependence. The combination of counseling and medication, however, is more effective than either alone. Thus, clinicians should encourage all individuals making a quit attempt to use both counseling and medication. 8. Telephone quitline counseling is effective with diverse populations and has broad reach. Therefore, both clinicians and health care delivery systems should ensure patient access to quitlines and promote quitline use. 9. If a tobacco user currently is unwilling to make a quit attempt, clinicians should use the motivational treatments shown in this Guideline to be effective in increasing future quit attempts. 10. Tobacco dependence treatments are both clinically effective and highly cost-effective relative to interventions for other clinical disorders. Providing coverage for these treatments increases quit rates. Insurers and purchasers should ensure that all insurance plans include the counseling and medication identified as effective in this Guideline as covered benefits.

This book is a guide to pharmacotherapy treatment of tobacco dependence. The 2020 American Thoracic Society clinical practice guidelines on treating tobacco dependence serves as the cornerstone for this work with its robust discussion of recommended treatment options and how to tailor treatment to specific patient populations. Tobacco dependence remains a major health concern for many adults and given the dramatic increase of youth electronic cigarette use, clinicians need a singular resource to treat these different populations. This book addresses that by following the three main points of how to best address the adverse impact of tobacco use on public health: 1) prevent initiation of tobacco use; 2) understand mechanisms of addiction; 3) effectively treat tobacco dependence. The book begins by describing the current patterns of product use, the adverse impact of tobacco on global health, and tobacco-related health disparities. Authors discuss both combustible and electronic tobacco products, as well as current research on the adverse impact of vaping and associated flavorings including menthol, role of the e-cigarette in cessation, and treatment of adolescent nicotine dependence. Chapters conclude with a discussion of specific tobacco control policies to improve overall public health. This is an ideal guide for pulmonologists, pediatricians, primary care physicians and other specialty providers who see patients with nicotine dependence. This book is also of interest to public health professions to help inform public health campaigns and treatment offerings to reduce overall tobacco product use through prevention and treatment.